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Background: Although granulomatous inflammation is a central feature of many disease processes, cellular
mechanisms of granuloma formation and persistence are poorly understood. Carbon nanoparticles, which can be
products of manufacture or the environment, have been associated with granulomatous disease. This paper utilizes
a previously described carbon nanoparticle granuloma model to address the issue of whether peroxisome
proliferator-activated receptor gamma (PPARγ), a nuclear transcription factor and negative regulator of inflammatory
cytokines might play a role in granulomatous lung disease. PPARγ is constitutively expressed in alveolar
macrophages from healthy individuals but is depressed in alveolar macrophages of patients with sarcoidosis, a
prototypical granulomatous disease. Our previous study of macrophage-specific PPARγ KO mice had revealed an
intrinsically inflammatory pulmonary environment with an elevated pro-inflammatory cytokines profile as compared
to wild-type mice. Based on such observations we hypothesized that PPARγ expression would be repressed in
alveolar macrophages from animals bearing granulomas induced by MWCNT instillation.
Methods: Wild-type C57Bl/6 and macrophage-specific PPARγ KO mice received oropharyngeal instillations of
multiwall carbon nanotubes (MWCNT) (100 μg). Bronchoalveolar lavage (BAL) cells, BAL fluids, and lung tissues were
obtained 60 days post-instillation for analysis of granuloma histology and pro-inflammatory cytokines (osteopontin,
CCL2, and interferon gamma [IFN-γ] mRNA and protein expression.
Results: In wild-type mice, alveolar macrophage PPARγ expression and activity were significantly reduced in
granuloma-bearing animals 60 days after MWCNT instillation. In macrophage-specific PPARγ KO mice, granuloma
formation was more extensive than in wild-type at 60 days after MWCNT instillation. PPARγ KO mice also
demonstrated elevated pro-inflammatory cytokine expression in lung tissue, laser-microdissected lung granulomas,
and BAL cells/fluids, at 60 days post MWCNT exposure.
Conclusions: Overall, data indicate that PPARγ deficiency promotes inflammation and granuloma formation,
suggesting that PPARγ functions as a negative regulator of chronic granulomatous inflammation.Background
Investment in nanotechnology is currently estimated to
constitute approximately 18 billion dollars nationally, with
commercial products ranging from sunscreens to bicycle
frames [1]. While the environmental and occupational
health impacts of nanotechnology remain to be estab-
lished, evidence of toxicity has emerged from some* Correspondence: thomassenm@ecu.edu
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reproduction in any medium, provided the orexperimental models where carbon-based nanomaterials
persist for long periods in lung tissue and induce granu-
lomatous changes (reviewed in [2,3]. Granulomatous disease
may occur in human lung in response to a wide spectrum
of environmental stimuli including intracellular pathogens,
inert materials, and organic antigens. In sarcoidosis, a proto-
typical granulomatous disease, the etiology remains obscure
[4]. Multiple occupational and environmental risk factors
have been linked to sarcoidosis, including exposure to parti-
culates from wood-burning stoves, fireplaces, firefighting,
and the World Trade Center disaster – conditions that
favor carbon nanotube formation in ambient air [5-8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation with instillation of single wall carbon nanotubes
[9-11]. We recently reported a novel murine model of
chronic granulomatous inflammation elicited by exposure
to multiwall carbon nanotubes (MWCNT) [12]. This
model demonstrated several key similarities with granu-
lomas encountered in human sarcoidosis: (a) chronicity
with persistence up to 90 days; (b) macrophage and T cell
recruitment; and (c) marked elevation of inflammatory
cytokines [12]. Previously published murine granuloma
models utilized sepharose beads to elicit acute granulomas
that formed and resolved within three weeks [13].
The transcription factor, PPARγ, is a critical regulator
of lipid and glucose metabolism but also recognized as a
negative regulator of genes linked to inflammatory
events [14]. Alveolar macrophages of healthy individuals
constitutively express PPARγ but PPARγ is deficient in
alveolar macrophages from patients with severe sarcoid-
osis, suggesting that this factor represents an important
regulator of inflammation [15]. Based on these observa-
tions we hypothesized that PPARγ might play a role in
the formation of MWCNT granulomas. To address this
hypothesis we first examined the effects of MWCNT in-
stillation on PPARγ expression and activity in wild-type
mice. Secondly, we investigated the effect of pre-existing
PPARγ deficiency on MWCNT-elicited granulomas by
utilizing macrophage-specific PPARγ KO mice. Results
suggested that PPARγ functions as a negative regulator of
granuloma formation in response to MWCNT instillation.Methods
All studies were conducted in conformity with Public
Health Service (PHS) Policy on humane care and use of
laboratory animals and were approved by the institu-
tional animal care committee.Mice
C57BL/6J wild-type mice from Jackson Laboratories and
macrophage-specific PPARγ KO conditional mice as pre-
viously described [16] were utilized in experiments as
indicated.Characterization of carbon nanotubes
MWCNTs (catalogue number 900–1501, lot GS1801),
grown via chemical vapor deposition, were obtained
from SES Research (Houston, TX). We determined the
structure of MWCNTs by scanning electron microscopy.
Nitrogen adsorption studies were performed using a phy-
sisorption analyzer (ASAP 2010; Micromeritics, Norcross,
GA). The details of the MWCNT characterization were
previously described by Huizar et al. [12].Instillation of carbon nanotubes
Procedures were performed according to the East Carolina
University Office of Environmental Health and Safety. An
oropharyngeal instillation was performed after sedation
with isofluorane. Sixty days after sham treatment (PBS/35%
surfactant) or exposure to 100 ug MWCNT, the mice were
sacrificed, and bronchoalveolar lavage (BAL) or lungs were
harvested for further analysis as previously described [12].
Histological analysis
Lungs were dissected and fixed in PBS-buffered 4% for-
maldehyde. A semiquantitative scoring system was devised
to allow for a relative comparison of the numbers and
quality of the granulomas formed in the C57 and PPARγ
mice strains. The glass slides with the Hematoxylin and
Eosin stained sections of lung from each of the experimen-
tal mice was assigned a score of between 0 and 5 by two
independent investigators using the following scoring sys-
tem: (score 0) – no granulomas or aggregates of macro-
phages seen; (score 1) - few small groups of macrophages
but no well-formed granulomas; (score 2) - scattered small
granulomas not easily seen on scanning power (20X);
(score 3) - scattered small granulomas easily seen on scan-
ning power (20X); (score 4) - scattered small granulomas
with occasional larger granulomas seen on scanning power
(20X); (score 5) - numerous large granulomas easily seen
on scanning power. The scores obtained by the two inves-
tigators were averaged for the final analysis.
Bronchoalveolar Lavage (BAL)
BAL cells were obtained as previously described [16].
Differential cell counts were determined from cytospins
stained with a modified Wright’s stain. Mean viability of
lavage cells was greater than 95% as determined by try-
pan blue dye exclusion.
RNA purification and analysis
Total RNA was extracted from total BAL cells by RNeasy
protocol (Qiagen, Valencia, CA). Expression of mRNA was
determined by real time qPCR using the ABI Prism 7300
Detection System (TaqMan; Applied Biosystems, Foster
City, CA) according to the manufacturer’s instructions.
RNA specimens were analyzed in duplicate using primer
sets for IFN-γ, osteopontin, and CCL2 (MCP-1). Threshold
cycle (CT) values for genes of interest were normalized to
a housekeeping gene glyceraldehyde 3 phosphate dehydro-
genase, (GAPDH) as previously described [16]. Data were
expressed as a fold change in mRNA expression of
MWCNT-bearing mice relative to sham control values.
Immunocytochemistry
Immunocytochemistry was performed on cytospin pre-
parations from freshly isolated C57Bl/6 alveolar macro-
phages for basal expression levels of PPARγ (Santa Cruz
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ormaldehyde–PBS, then permeabilized with Triton X-100
and stained with anti-PPARγ antibody at 1:500 dilution,
followed by Alexa conjugated goat anti rabbit IgG (Invitro-
gen). Staining of lung tissues with antibody to IFN-γ, CD3
and MOMA2 (anti-monocyte and macrophage) was car-
ried out as described previously [16]. Slides were counter
stained with Propidium Iodide (PI) [Vector Laboratories]
or DAPI (Invitrogen) to facilitate nuclear localization.
Laser-capture microdissection
Lung tissues from sham-treated mice (controls) and
both granulomatous, and non-granulomatous lungA
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Figure 1 PPARγ expression and activity are decreased in BAL from M
from MWCNT or sham-treated mice (n=4/group) were analyzed by quantit
post MWCNT instillation. Immunocytochemistry of alveolar macrophages c
PPARγ protein at 60 days after MWCNT instillation (C) compared to sham c
(D) Quantification of PPARγ fluorescence intensity of alveolar macrophages
exposure significantly reduced PPARγ expression (n=5/group). (E) PPARγ bi
MWCNT-treated mice (n=3/group) as measured by ELISA.tissues from MWCNT-instilled mice were dissected
using a Zeiss PALM IV LCM (Carl Zeiss MicroImaging
LLC, Thornwood, New York) system. Frozen sections
of the lung were processed as previously described [12].
RNA was extracted from tissue sections, converted into
cDNA or preamplified, as described previously [12].
Quantitation of cytokine proteins
Murine osteopontin was quantified in BAL fluids using an
ELISA assay (R&D stystems, Minneapolis, MN), as previ-
ously described [12]. Murine IFN-γ and CCL2 (MCP-1)
were quantified by electrochemiluminescence detection
(Meso Scale Diagnostics, Gaithersburg, MD).E
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Figure 2 Extent of granuloma involvement is greater in PPARγ KO than in wild-type lung tissues. Control lung sections were derived from
sham treated wild-type C57/Bl6 (A) and (B) sham treated PPARγ KO mice (200X). (C) Lung sections from C57Bl/6 mice at 60 days after MWCNT
instillation show a few aggregates of cells resembling macrophages visible at 100X. (E) At higher power, the aggregates of C57Bl/6 macrophages
do not appear to have coalesced into a recognizable granuloma, with the individual cytoplasmic borders of the macrophages easily seen (400X).
(D) In contrast, lungs from the PPARγ KO mice demonstrate numerous granulomas containing relatively large aggregates of MWCNT (100X).
(F) At higher power, the PPARγ KO macrophages appear to have coalesced into a granuloma, with the syncytial-like loss of cytoplasmic borders
characteristic of a well-formed granuloma (400X). (G) Analysis by scoring index indicates increased pulmonary granuloma size (p = 0.01) in PPARγ
KO compared to wild-type C57Bl/6 mice (n=6/group).
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Data were analyzed by student’s t-test or Mann–Whitney
using Prism software (GraphPad, Inc., San Diego, CA.).
Values from treated were compared to sham treated ani-
mals. Data are expressed as mean ± SEM. Significance
was defined as p ≤ 0.05.
Results
PPARγ expression and activity are decreased in alveolar
macrophages from MWCNT-instilled wild-type C57Bl/6 mice
Analysis of mRNA derived from BAL cells revealed signifi-
cant reduction of PPARγ mRNA expression in wild-type
mice at 60 days after MWCNT (100 ug) instillation as com-
pared to sham controls (Figure 1A). Direct examination of
alveolar macrophage PPARγ expression by immunocyto-
chemistry confirmed reduction of PPARγ protein at 60 days
of MWCNT exposure (Figures 1B-D). Similarly, PPARγ
DNA-binding activity also decreased (Figure 1E). Thus all
parameters indicated that MWCNT instillation into the
lung induced severe and significant repression of alveolarA
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mice exceeds that of wild-type animals
To examine the effects of pre-existing PPARγ deficiency
on MWCNT granuloma formation, MWCNT (100 μg)
were instilled into lungs of macrophage-specific PPARγ
KO and into wild-type mice. For reference, histologic
sections from untreated C57/Bl/6 (Figure 2A) and
PPARγ KO (Figure 2B) are provided. Granuloma forma-
tion was evaluated at 60 days of MWCNT exposure.
Histologic comparison of wild-type C57Bl/6 (Figure 2C
and E) and PPARγ KO (Figure 2D and F) lung tissues
was carried out using a simplified scoring system taking
into account size and frequency of granulomas. Results
indicated that the extent of granuloma formation in
PPARγ KO mice was significantly (p = 0.01) greater than
in wild-type mice (Figure 2E). control
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Figure 4 (See legend on next page.)
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Figure 4 Granulomatous tissues contain elevated pro-inflammatory cytokine expression in macrophage-specific PPARγ KO mice. QPCR
of PPARγ KO lung tissues obtained by laser capture microdissection reveal elevated mRNA expression of osteopontin (A) (p = 0.03) and CCL2
(B) (p = 0.04) in granulomatous foci (MWCNT) compared to control wild type lung tissues (n=2/group). Unstained PPARγ KO lung tissue sections
(200x) were obtained from control lung (C) or MWCNT-instilled lung (E). Arrows point to MWCNT within granulomas (E). Additional lung tissue
sections were stained with antibody to IFN-γ and counterstained with propidium iodide to localize nuclei: (D) Sham control lung; (F) MWCNT-
instilled lung. Arrows point to IFN-γ -positive cells within granulomatous foci (F).
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In order to identify cell types associated with granuloma-
tous tissue, lung sections from nanotube-instilled mice
were stained with anti-CD3 (T cells) and anti-MOMA
(monocytes and macrophages). Figures 3A and B show
minimal CD3+ staining in tissue sections from sham trea-
ted C57/Bl6 or PPARγ KO control mice. In contrast,
marked CD3+ staining is apparent in association with
granulomas in nanotube-instilled mice (Figure 3C). Simi-
larly, Figures 3D and E demonstrate minimal MOMA
staining in lung tissues from sham treated mice but prom-
inent MOMA staining localizing with granulomatous foci
in nanotube-instilled mice (Figure 3F).
Pro-inflammatory cytokines are elevated in
granulomatous tissue
BAL cell counts were not affected by MWCNT exposure
(data not shown), however, as we noted previously, lympho-
cyte counts from untreated PPARγ KO mice (7.6 ± 1.4%)
were significantly (p = 0.005) higher than those of wild-type
(3.2 ± 0.6%) [16]. Examination of lung tissues by laser
microdissection and qPCR revealed that mRNA expres-
sion of osteopontin, a granuloma-promoting chemokine
[17], was elevated in granulomatous foci compared to wild
type sham control lung tissues (Figure 4A). Previously in
wild-type mice we found that osteopontin was elevated
20-fold in granulomatous foci at 60 days whereas non-
granulomatous tissue did not differ from untreated lung
tissue [12]. Elevated expression of the monocyte chemo-
kine, CCL2 [18] was also prominent in granuloma foci
compared to control wild type tissue (Figure 4B). CCL2
expression in granulomas was also investigated previously
in wild-type mice and found to be elevated 6-fold compared
with lung tissue from controls [12]. Although elevation of
mRNA from the prototypical inflammatory cytokine, inter-
feron gamma (IFN-γ), was below detectable limits in LCM
samples of granulomatous foci, immunostaining confirmed
the presence of numerous IFN-γ-expressing cells within
60-day MWCNT-induced granulomas (Figures 4E and F).
In contrast, sham control lung tissue contained few such
cells (Figures 4C and D).
Pro-inflammatory Cytokines are elevated in BAL cells and
fluids from MWCNT-instilled PPARγ KO mice
Because previous findings in BAL cells from wild-type
mice indicated elevation of pro-inflammatory cytokines at60 days after MWCNT instillation [12], we investigated
BAL cells in macrophage-specific PPARγ KO mice. Sixty
days after MWCNT instillation, PPARγ KO BAL cells
contained elevated mRNA expression levels of osteopon-
tin (Figure 5A) and CCL2 (Figure 5B) compared to sham
C57/Bl6 or PPARγ KO controls. IFN-γ mRNA was also
elevated in nanotube-instilled PPARγ KO compared to
sham control PPARγ KO (Figure 5C). Previously, we had
reported that IFN-γ mRNA was elevated in untreated
PPARγ KO mice compared to untreated wild-type C57Bl/6
[13]. Analysis of BAL fluids also demonstrated elevated
osteopontin (Figure 5D) and CCL2 (Figure 5E) proteins at
60 days post-MWCNT instillation. Although IFN-γ pro-
tein was apparent within granulomas (Figure 4F), IFN-γ
was below detectable limits in BAL fluids.
Discussion
Data from the present study indicate that both expression
and activity of PPARγ in alveolar macrophages from wild-
type mice were significantly diminished at 60 days after
pulmonary instillation of nanotubes. These data supported
previous findings of reduced PPARγ in alveolar macro-
phages from patients with the human chronic granuloma-
tous disease, sarcoidosis [15]. Investigation of the effects of
pre-existing PPARγ deficiency was achieved by utilizing a
conditional mouse model in which PPARγ was specifically
disrupted in macrophages and neutrophils [16]. Results
from this model revealed elevated pro-inflammatory cyto-
kines in granulomatous tissue, BAL cells, and BAL fluids
60 days post-instillation of MWCNT. Histological examin-
ation of lung tissues from MWCNT-exposed animals also
indicated a greater extent of granuloma formation in
PPARγ KO mice than in MWCNT-exposed wild-type
animals.
The stimulatory effects of MWCNT instillation on cyto-
kine production were noted previously in wild-type C57Bl/
6 mice [12]. The current report also indicates that
MWCNTs repress PPARγ expression in wild-type mice,
raising the question of whether PPARγ deficiency augments
pro-inflammatory cytokine expression. Previously, we
reported that IFN-γ and other Th1-type pro-inflammatory
cytokines/chemokines were intrinsically elevated in un-
treated PPARγ KO mice compared to wild-type mice [16].
This increased cytokine expression was reduced by
in vivo administration of a PPARγ lentivirus construct
[16]. Additionally, application of a PPARγ antagonist to
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Figure 5 (See legend on next page.)
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Figure 5 Pro-inflammatory cytokines are elevated in BAL cells and fluids from macrophage-specific PPARγ KO mice 60 days post-
instillation of MWCNT. (A) MWCNT instillation of PPARγ KO mice (n=8) significantly increases BAL cell osteopontin mRNA expression compared
to sham C57/Bl6 (n=7) or PPARγ KO (n=6) controls. (B). CCL2 mRNA expression is increased in MWCNT-instilled PPARγ KO mice (n=11) compared
to sham C57/Bl6 (n=9) or PPARγ KO (n=8) controls. (C) IFNγ mRNA expression is increased in MWCNT-instilled PPARγ KO (n=11) compared to
PPARγ KO controls (n=8). BAL fluids from MWCNT-exposed PPARγ KO mice contain elevated: (D) osteopontin compared to sham C57Bl/6 or
PPARγ KO controls (n=8/group); and (E) CCL2 (n=6/group) proteins compared to sham controls. CCL2 levels of C57Bl/6 and PPARγ KO sham
control groups were below detectable limits of the assay (12.8 pg/ml).
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in an elevated cytokine profile resembling the PPARγ KO
phenotype [16]. When taken together, current and previ-
ous data allows us to hypothesize that healthy alveolar
macrophage PPARγ expression is necessary to restrain
pro-inflammatory cytokine expression and maintain pul-
monary integrity.
Despite the presence of elevated intrinsic cytokines in
PPARγ KO mice compared to wild-type controls,
MWCNT instillation further elevated cytokine expres-
sion when compared to sham PPARγ KO controls.
Cytokines elevated by MWCNT exposure in PPARγ KO
mice included osteopontin, which was found in granu-
loma tissue, BAL cells and fluids. Osteopontin is a noncol-
lagenous matrix protein with cytokine properties that
include cellular activation, migration and cell-matrix inter-
action in T lymphocytes, macrophages, and fibroblasts
[17,19]. Osteopontin is abundant in granulomas of varying
etiology [20] and deficiency of this molecule in null mice
impairs granuloma formation [17]. Gene expression of
osteopontin is antagonized by PPARγ ligands, thus sug-
gesting a direct avenue by which PPARγ may attenuate
granuloma formation [21].
Interestingly, osteopontin is reported to increase T cell
expression of IFN-γ [22] and IFN-γ has been shown to in-
duce osteopontin in monocyte-derived macrophages [23].
Thus it is possible that IFN-γ and osteopontin may inter-
act in a positive feedback loop to maintain high levels in
untreated PPARγ KO mice. In human sarcoidosis, both
osteopontin and IFN-γ are prominent in granulomas
[24,25] and IFN-γ is persistently elevated in sarcoidosis
BAL cells [26-28].
BAL cells from untreated PPARγ KO mice also exhib-
ited higher intrinsic mRNA levels of CCL2 (MCP-1), a po-
tent monocyte chemokine [18] than did BAL cells from
wild-type mice. Previously we noted that CCL2 expression
in wild-type C57Bl/6 mice became elevated at sixty days
post-instillation of MWCNT [12]. CCL2 was also further
elevated in PPARγ KO BAL cells at 60 days post MWCNT
instillation. Interestingly, elevated CCL2 is also present in
sarcoidosis BAL cells and fluids [29] as well as serum [30].
Overall, the evidence for elevated CCL2 in human sarcoid-
osis and in MWCNT-instilled wild-type and PPARγ KO
mice suggests that this chemokine is an important elem-
ent of inflammatory pulmonary granuloma formation.PPARγ plays an important role in the negative regula-
tion of inflammation by inhibiting the gene expression of
numerous cytokines including osteopontin and CCL2.
Reported mechanisms of PPARγ-mediated transrepression
include: (a) binding of NF-κB, (b) induction of IκBα ex-
pression (c) inhibition of MAPK activity, (d) competi-
tion for coactivators (e.g. CREB-binding proteins), and
(e) blocking clearance of NCoR corepressor complexes
[31]. Thus in the current study, we hypothesize that a lack
of PPARγ-mediated transrepression may be responsible
for augmenting granulomatous reactions in macrophage-
specific PPARγ KO mice via concurrent upregulation of
cytokines (osteopontin and CCL2) involved in granuloma
formation.Conclusion
Chronic granulomatous inflammation in response to
chemical or biological insult has proven to be a difficult
disease to control, despite years of research. Nanoparticles
have only recently been implicated as potential causes of
granuloma formation that may relate to either occupa-
tional or environmental exposures [32]. The persistent na-
ture of the MWCNT granuloma model parallels that of
human granulomatous disorders and emphasizes the ap-
plicability of this model to studies of human granuloma
pathophysiology. The current findings provide a new per-
spective on the critical role of alveolar macrophage PPARγ
in lung homeostasis by demonstrating negative effects on
granuloma formation.
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